Rawlins, adaptive licensing and EU regulators' fight for fair remuneration*
This article was originally published in SRA
When Professor Sir Michael Rawlins retired earlier this year after more than a decade as chair of UK health technology assessment body NICE, we suspected we hadn’t seen the last of him. We were right. Sir Michael, who was chair of NICE from its creation in 1999 to April this year, has been appointed to the board of directors of Intra-Cellular Therapies, a US biopharmaceutical company focused on the development of therapeutics for CNS disorders1.